Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Key Event: The reporting period is dominated by the consummation of the acquisition of Guidant Corporation on April 21, 2006. This transaction significantly diversified Boston Scientific's revenue streams into the Cardiac Rhythm Management (CRM) market. Concurrently, Abbott Laboratories acquired Guidant's vascular intervention and endovascular solutions businesses, with Boston Scientific retaining rights to share the drug-eluting stent technology.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2006 | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2005 |
|---|---|---|---|---|
| Net Sales | $2,026 | $1,511 | $5,756 | $4,743 |
| Gross Profit | $1,396 | $1,168 | $4,075 | $3,699 |
| Gross Margin % | 68.9% | 77.3% | 70.8% | 78.0% |
| Operating Income/(Loss) | $195 | $(336) | $(3,233) | $503 |
| Net Income/(Loss) | $76 | $(269) | $(3,854) | $294 |
| Diluted EPS | $0.05 | $(0.33) | $(3.19) | $0.35 |
| Cash from Operations (9mo) | $1,480 | $393 | ||
| Total Debt (Gross) | $8,898 (as of Sep 30, 2006) | |||
| Cash & Equivalents | $1,541 (as of Sep 30, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 34% in Q3 and 21% for the nine-month period, primarily driven by the inclusion of Guidant's CRM and Cardiac Surgery divisions ($491 million in Q3; $965 million YTD).
- Profitability Impact: Despite revenue growth, the company reported a net loss of $3.85 billion for the nine months ended September 30, 2006, compared to net income of $294 million in the prior year. This was driven by significant non-recurring charges.
- Acquisition Charges: The nine-month loss included approximately $4.12 billion in purchased research and development (R&D) expenses related to the Guidant acquisition and $279 million in step-up value of acquired inventory sold.
- Debt Levels: Total debt increased from $2.02 billion at year-end 2005 to $8.90 billion at September 30, 2006, to finance the Guidant acquisition. Interest expense rose to $291 million for the nine-month period (vs. $58 million prior year).
- Margin Compression: Gross margin decreased by 7.2 percentage points YTD due to Guidant-related costs (inventory step-up and technology offering charges) and expenses related to "Project Horizon" (quality system improvements).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- CRM Market Recovery: Management expects the CRM market growth rate to recover over several years but notes no assurance of returning to historical rates. The company is focused on regaining physician confidence following field actions (product recalls) regarding defibrillators and pacemakers.
- Stent Market: Drug-eluting stent penetration rates in the U.S. declined slightly in Q3 due to concerns over late stent thrombosis. The company expects to launch the TAXUS Liberté stent in the U.S. in mid-2007, pending FDA resolution of warning letters.
- Integration: The company anticipates continued integration and restructuring costs. Efficiencies are expected to offset these costs over time, but no assurances are provided.
Risks and Contingencies
- Regulatory Actions: The company received FDA warning letters in late 2005 and early 2006 regarding manufacturing quality systems at multiple facilities. Failure to resolve these could lead to product seizures, injunctions, or penalties.
- Litigation: Significant intellectual property litigation exists with competitors (Johnson & Johnson, Medtronic). Additionally, the acquisition of Guidant brought substantial product liability and securities litigation risks, including over 700 individual lawsuits and class actions regarding defibrillators and pacemakers.
- Debt Covenants: The company must maintain a debt-to-pro forma EBITDA ratio of less than 4.5 to 1.0 through 2007. As of September 30, 2006, the ratio was 3.5 to 1.0.
Unusual Items
- Abbott Transaction: Abbott purchased $1.4 billion of Boston Scientific stock and loaned the company $900 million. A "sharing of proceeds" feature resulted in a $100 million fair value adjustment expense for the nine-month period.
- Program Cancellations: The company cancelled the TriVascular AAA stent-graft program, resulting in a $67 million credit to purchased R&D and $23 million charge to amortization.
Investor Verification Checklist
- Debt Servicing: Verify the company's ability to service $8.9 billion in debt with a weighted average interest rate of 6.13% given the current operating loss.
- FDA Compliance: Monitor the status of FDA re-inspections and the resolution of warning letters, as this directly impacts the launch of the TAXUS Liberté stent and export capabilities.
- CRM Market Share: Assess the effectiveness of the company's strategy to regain market share in the CRM sector following the Guidant acquisition and subsequent product recalls.
- Integration Costs: Track actual integration and restructuring costs against management's projections to determine if synergies are being realized.
- Litigation Exposure: Review updates on major patent disputes (Johnson & Johnson, Medtronic) and the volume of product liability claims inherited from Guidant.